L-Ornithine L-Aspartate
Reading File
Finding Sources
Searching PubMed
"L-ornithine L-aspartate" AND "hepatic encephalopathy"
Searching the Web
L-Ornithine L-Aspartate LOLA mechanism action clinical uses hepatic encephalopathy
Reading File
Reading File
Reading Article
PMID: 38403493
Reading Article
PMID: 34822189
I now have comprehensive information to give a detailed answer on LOLA.
L-Ornithine L-Aspartate (LOLA)
What Is It?
L-Ornithine L-Aspartate (LOLA) is a stable salt formed by the combination of two endogenous amino acids - L-ornithine and L-aspartate. It is the primary pharmacological agent used to lower blood ammonia and is most widely applied in the management of hepatic encephalopathy (HE) in cirrhotic patients. It has been in clinical use for over 50 years and is available in both intravenous and oral formulations.
Mechanism of Action
LOLA lowers plasma ammonia via two distinct and complementary pathways:
1. Hepatic Urea Cycle (Periportal Hepatocytes)
- L-Ornithine acts as a direct substrate and allosteric activator of two key urea cycle enzymes: carbamoyl phosphate synthetase I (CPS-I) and ornithine carbamoyltransferase (OCT)
- L-Aspartate donates the second nitrogen atom required for urea synthesis (via argininosuccinate)
- Together they accelerate hepatic conversion of ammonia into urea, which is renally excreted
2. Glutamine Synthesis (Perivenous Hepatocytes, Skeletal Muscle, Brain)
- Both ornithine and aspartate serve as substrates for transamination reactions, generating L-glutamate
- L-glutamate is the obligate substrate for glutamine synthetase (GS)
- GS catalyzes: NH₃ + Glutamate → Glutamine (non-toxic, water-soluble)
- This peripheral ammonia fixation into glutamine is especially important when hepatic urea cycle capacity is impaired (as in cirrhosis)
- Skeletal muscle GS activity is particularly critical in cirrhosis, where muscle becomes the dominant site of ammonia detoxification
As noted in Yamada's Textbook of Gastroenterology: "LOLA helps metabolism of ammonia at the liver level and peripherally it acts on glutamine synthetase and increases glutamine levels and may improve sarcopenia."
Clinical Indications
| Indication | Evidence |
|---|---|
| Overt Hepatic Encephalopathy (OHE) - acute | Good; IV LOLA shown to improve grade and reduce mortality |
| Minimal HE (MHE) | Meta-analysis (2024): RR 2.26 for reversal vs. placebo |
| Post-TIPS HE prevention | Demonstrated benefit in lowering postprandial ammonia |
| Non-alcoholic Fatty Liver Disease (NAFLD) | Emerging/investigational |
Dosing
| Route | Dose | Notes |
|---|---|---|
| IV | 30 g over 24 hours (continuous infusion) | For acute/severe OHE (grade III-IV); 5-day course studied |
| Oral | 3-9 g three times daily (standard granule sachets) | For MHE and secondary prophylaxis; some references note lower efficacy vs. IV for acute OHE |
Place in Therapy
According to Current Surgical Therapy (14e), LOLA is classified as an alternative/add-on therapy - not a first-line agent in most Western guidelines:
- First-line: Lactulose ± Rifaximin
- LOLA: Add-on or alternative, especially when first-line therapy is insufficient or not tolerated
- Not widely available in the United States (IV form)
- Widely used across Asia, Europe, and Latin America
A 2024 meta-analysis (He et al., Arab J Gastroenterol) of 6 RCTs (292 patients) found LOLA significantly better than placebo for reversing MHE (RR 2.26, 95% CI 1.53-3.35) and preventing progression to OHE (RR 0.22, 95% CI 0.076-0.637).
A pivotal double-blind RCT (Jain et al., Hepatology 2022) in 140 patients with grade III-IV OHE found that IV LOLA (30 g/day) + lactulose + rifaximin vs. placebo + lactulose + rifaximin achieved:
- HE grade improvement: 92.5% vs. 66% (p < 0.001)
- 28-day mortality: 16.4% vs. 41.8% (p = 0.001)
- Faster recovery and greater reductions in blood ammonia, IL-6, and TNF-alpha
A 2025 systematic review (Zhang et al., Front Med) confirmed that LOLA + lactulose combination is superior to either agent alone, with synergistic effects on ammonia metabolism, gut microenvironment, and inflammatory markers.
Contraindications & Precautions
- Severe renal impairment (serum creatinine > 3 mg/dL): Contraindicated, because urea produced must be renally excreted
- Use with caution in any significant renal dysfunction
Adverse Effects
LOLA is generally very well tolerated:
- Nausea/dyspepsia: mild, in < 2% of patients
- Nausea and vomiting: occasionally with rapid IV infusion (infuse slowly)
- No significant hepatotoxicity or serious adverse effects reported in clinical trials
Key Takeaways
- LOLA lowers ammonia via dual mechanisms: hepatic urea cycle (ornithine/aspartate as direct substrates) and peripheral glutamine synthesis (muscle/brain)
- Most effective in the IV form for acute, severe HE (grade III-IV); oral form more practical for MHE and prophylaxis
- Comparable to lactulose for acute OHE management; combination with lactulose and rifaximin appears to be superior to standard therapy alone
- Well-tolerated with minimal side effects; avoid in severe renal failure
- Not currently FDA-approved in the US for this indication, but widely used internationally
Sources: Current Surgical Therapy 14e | Yamada's Textbook of Gastroenterology 7e | Rosen's Emergency Medicine | Bradley and Daroff's Neurology in Clinical Practice | He et al. PMID 38403493 | Jain et al. PMID 34822189 | Zhang et al. PMID 40370740
This is a shared conversation. Sign in to Orris to start your own chat.